US 12,065,498 B2
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
Peter Emtage, Lafayette, CA (US); Stephen Santoro, Daly City, CA (US); and Stephanie Secrest, San Francisco, CA (US)
Assigned to Cell Design Labs, Inc., Emeryville, CA (US)
Filed by Cell Design Labs, Inc., Emeryville, CA (US)
Filed on Sep. 27, 2018, as Appl. No. 16/144,003.
Claims priority of provisional application 62/566,025, filed on Sep. 29, 2017.
Prior Publication US 2019/0194340 A1, Jun. 27, 2019
Int. Cl. C07K 16/28 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/00 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/283 (2013.01); A61K 38/00 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)] 11 Claims
 
1. A chimeric antigen receptor (CAR) comprising:
a first antigen-binding domain that binds specifically to B-cell maturation antigen (BCMA), the first antigen binding domain comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 101, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 102, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 103, VH CDR1 comprising the amino acid sequence of SEQ ID NO: 104, a VL VH CDR2 comprising the amino acid sequence of SEQ ID NO: 105, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 106;
a second antigen-binding domain that binds specifically to CD307e, the second antigen binding domain comprising a first set of CDRs, a second set of CDRs, or a third set of CDRs, wherein,
the first set of CDRs comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 107, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 108, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 109, a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 110, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 111, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 112;
the second set of CDRs comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 119, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 120, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 121, a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 122, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 123, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 124; and
the third set of CDRs comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 125, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 126, a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 127, a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 128, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 129, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 130;
a linker that is positioned between the first antigen-binding domain and the second antigen-binding domain;
a transmembrane domain comprising the amino acid sequence of SEQ ID NO: 48;
a hinge sequence that is positioned between the first antigen-binding domain and the transmembrane domain comprising the amino acid sequence of SEQ ID NO: 81;
a co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 93; and
an intracellular signaling domain comprising the amino acid sequence of SEQ ID NO: 85.